Management of pregnancy and delivery in congenital fibrinogen disorders: communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen

J Thromb Haemost. 2024 May;22(5):1516-1521. doi: 10.1016/j.jtha.2024.01.008. Epub 2024 Jan 22.


Congenital fibrinogen disorders (CFDs) are a heterogeneous group of rare congenital quantitative and/or qualitative fibrinogen deficiencies. The spectrum of molecular anomalies is broad, leading to several subtypes of fibrinogen disorders (ie, afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia). Pregnancy in women with CFDs is a high-risk clinical situation, with an increased tendency for miscarriages, bleeding, and thrombosis. Even though it is well established that management of such pregnancies requires a multidisciplinary approach involving specialists (hematologists and maternal/fetal medicine experts with expertise in the management of inherited bleeding disorders), specific guidelines are lacking. In this International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee communication, we aim to propose an expert consensus opinion with literature evidence where available on the strategy for management of pregnancy, delivery, and puerperium in CFDs.

Keywords: afibrinogenemia; congenital; fibrinogen; fibrinogen deficiency; hypofibrinogenemia; pregnancy.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Afibrinogenemia* / blood
  • Afibrinogenemia* / diagnosis
  • Afibrinogenemia* / therapy
  • Consensus
  • Delivery, Obstetric
  • Factor XIII / metabolism
  • Female
  • Fibrinogen* / metabolism
  • Fibrinogen* / therapeutic use
  • Humans
  • Pregnancy
  • Pregnancy Complications, Hematologic* / blood
  • Pregnancy Complications, Hematologic* / diagnosis
  • Pregnancy Complications, Hematologic* / therapy


  • Fibrinogen
  • Factor XIII